Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol

  • If approved, inclisiran will be the first and only small interfering RNA (siRNA) in Europe for patients with hypercholesterolemia or mixed dyslipidemia1
  • Cardiovascular disease (CVD) claims 3.9 million lives annually in Europe2, and 80% of high-risk patients do not reach guideline-recommended low-density lipoprotein cholesterol (LDL-C) targets despite the widespread …
/by
Sandoz Donates 20 critically needed generic medicines to hospitals and dispensaries in continued support of the people of Beirut

In continued support of the people of Beirut, Lebanon impacted by the August 4 port explosion and the ongoing rebuilding efforts, Sandoz has donated 20 critically needed generic medicines through the non-governmental organization (NGO), Beit el Baraka.

The donations will be disbursed to severely damaged hospitals and also dispensaries in order to best respond to the ongoing devastation, and supports the initial monetary donation from Novartis to the Red Cross for early relief efforts.

Sandoz is thankful for the safety of our associates who live and work in Lebanon, and grateful …

/by

Novartis received European Medicines Agency (EMA) PRIME designation for iptacopan (LNP) in C3 glomerulopathy (C3G)

  • The European Medicines Agency has granted iptacopan a priority medicines (PRIME) designation in C3 glomerulopathy (C3G). 
  • PRIME is granted for medicines that may offer major therapeutic advance or benefit patients without treatment options.
  • C3 glomerulopathy (C3G) is a rare renal disease, affecting young patients with a poor prognosis and significant unmet need.1 …
/by

World Sight Day 2020

2.2 billion people are blind or visually impaired worldwide. Half of them lack access to eye care. Together, we are working to change that. This World Sight Day, Novartis is proud to partner with the International Agency for the Prevention of Blindness (IAPB) to expand equitable access to eye care in remote communities with the initiation of early detection eye health screening programs.

…
/by

Meet a visionary who beat the odds to realize his vision of inclusive eye care

In Rwanda, it is estimated that more than 65,000 people (0.6% of the population) are blind in both eyes and that 12% of the population have a correctable refractive error or blurred vision, requiring corrective lenses.1

In this country of more than 12 million residents, there are only 18 ophthalmologists.

As one of those ophthalmologists, and the only one within a catchment area of 1.2 million people from Rwanda and nearby countries, Dr. Theophile Tuyisabe has an enormous responsibility. Each day he commutes an hour to the Eye Unit at the Kabgayi Hospital, treats …

/by

New Phase III analysis demonstrates Novartis Beovu® showed improvement in best-corrected visual acuity in wet AMD patients with early persistent fluid

  • In a post-hoc analysis of HAWK and HARRIER, fewer Beovu (brolucizumab) patients had early persistent fluid (12.5% vs. 20.4% of aflibercept patients), defined as the presence of intra-retinal fluid and/or sub-retinal fluid through week 12 of treatment1
  • Patients with early persistent fluid treated with Beovu experienced greater gains in best-corrected visual acuity (BCVA) at week 96 …
/by

Zolgensma® data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonged event-free survival, increased motor function and milestone achievement

  • Nearly two-thirds of patients (65.6%) in STR1VE-EU have already achieved developmental motor milestones not observed in the natural history of SMA Type 1 at a mean duration of follow-up of 10.6 months, including patients with a more severe phenotype compared to previous studies
  • Two-thirds of patients (66.7%) were free of feeding support, an important indicator of stabilization/halting of disease progression
  • New interim Phase 3 STR1VE-EU data presented at WMS support the robust clinical evidence that …
/by
Sandoz launches its first RFID-tagged critical injectable medicines with Kit Check to optimize supply chain and automate restocking in US hospitals
  • First three Sandoz medicines labeled with RFID technology will be available in US hospitals starting in October, followed by several more through Q1 2021
  • Sandoz and Kit Check together provide comprehensive solutions to hospital customers to lower costs, reduce risks and treat patients safely and more efficiently
  • Advanced tracking technology streamlines inventory, workflow and auditing processes, further advancing Sandoz goal of being supplier of choice in hospitals

…

/by

Life Science Companies and the Bill & Melinda Gates Foundation: Joint Communique

COVID-19’s existence anywhere poses a threat to communities everywhere. The health, social, and economic impacts can only be addressed through the collective actions of stakeholders across private, public, and philanthropic sectors in partnership with civil society. As organizations dedicated to improving and protecting global health, with our varied skills, roles, and resources, we remain committed to doing our part in ending this pandemic worldwide. Earlier this year AstraZeneca; Bayer; bioMérieux; Boehringer Ingelheim; Bristol Myers Squibb; Eisai; Eli Lilly; Gilead; GSK; Johnson & …

/by

World Heart Day 2020: From our heart to yours

For the past six decades, Novartis has been working to advance heart health around the world, from transforming the standard of care for cardiovascular conditions to strengthening healthcare systems in lower income communities.

Cardiovascular disease (CVD) is a general term for conditions affecting the heart or blood vessels. Although average CVD mortality rates have fallen by 61% over the 50-year period since 19601, CVD remains the number one killer worldwide, causing one out of three deaths globally2.

CVD has many causes: from smoking, diabetes, high …

/by